Obstructive jaundice occurs when something physically blocks the bile ducts, preventing bile from draining out of the liver and into the intestine. The backup of bile causes bilirubin to spill into the bloodstream, turning the skin and whites of the eyes yellow. Unlike other forms of jaundice caused by liver cell damage or excessive breakdown of red blood cells, the obstruction here is mechanical, and that distinction drives everything about how it is diagnosed and treated.
How Bile Gets Blocked
Bile is produced in the liver and travels through a branching network of ducts that merge into the common bile duct before emptying into the small intestine. When any part of that plumbing is blocked, bile pools upstream. Bilirubin, the yellow-orange pigment that gives bile its color, accumulates in the blood instead. The liver keeps making bile, but with nowhere to go it backs up into the bloodstream, staining tissues and eventually reaching the kidneys, which is why people with obstructive jaundice often produce dark-colored urine even before the yellowing of the skin becomes obvious.
At the cellular level, prolonged obstruction triggers changes in the liver’s own transport machinery. Proteins on liver cell membranes that normally pump bile components outward start to malfunction, and in a kind of damage-control response, the liver reroutes some bile acids back into the blood for the kidneys to excrete in urine. That adaptive response helps limit toxic buildup inside liver cells but does nothing to fix the underlying blockage.
What Causes the Blockage
The causes split broadly into benign and malignant. Among benign causes, gallstones lodged in the common bile duct are the most frequent culprit. Bile duct stones can present with anything from no symptoms at all to sudden, intense abdominal pain, pancreatitis, jaundice, or a dangerous infection of the bile ducts called cholangitis.
A less common benign cause is Mirizzi syndrome, where a gallstone becomes impacted at the neck of the gallbladder and presses on the adjacent bile duct from the outside. Over time the stone can erode through the wall, creating an abnormal connection between the gallbladder and the bile duct. Mirizzi syndrome is tricky because it mimics a bile duct tumor on imaging, and surgeons sometimes discover it only during an operation.
On the malignant side, tumors of the pancreatic head are the classic cause. Because the common bile duct passes through or alongside the head of the pancreas, even a small tumor there can squeeze the duct shut. Cholestatic symptoms, meaning jaundice, pale stools, dark urine, and itching, are more common when the cancer is confined to the pancreatic head, and paradoxically this means jaundice sometimes leads to an earlier diagnosis compared with tumors elsewhere in the pancreas. Cholangiocarcinoma, a cancer arising from the bile duct lining itself, is another important malignant cause. When it occurs at the junction where the right and left hepatic ducts meet, it is called a hilar cholangiocarcinoma, and jaundice is its most common symptom, present in roughly nine out of ten patients at the time of diagnosis.
A clinical sign that helps distinguish stones from tumors is the so-called Courvoisier sign: a palpable, painlessly enlarged gallbladder in a jaundiced patient suggests malignant obstruction rather than stones. When a tumor simultaneously dilates both the bile duct and the pancreatic duct, imaging reveals a “double duct sign” that further raises suspicion for cancer.
Recognizing the Symptoms
The hallmark triad is yellow skin and eyes, dark urine, and pale or clay-colored stools. The pale stools occur because bilirubin, which normally gives stool its brown color, never reaches the intestine. Itching is another prominent symptom and can be maddening. The exact cause of the itch is still debated; endogenous opioids, serotonin, certain steroids, and a lipid called lysophosphatidic acid all seem to play a role, but no single molecule has been pinpointed as the definitive trigger.
Pain depends on the cause. A gallstone passing through the duct often produces sharp, episodic biliary colic, whereas a slowly growing tumor may cause painless jaundice for weeks before any discomfort appears. Weight loss and a vague, gnawing abdominal ache alongside painless jaundice should raise concern for a pancreatic or bile duct malignancy.
What Blood Tests Reveal
Laboratory results in obstructive jaundice tend to follow a recognizable pattern, but the details vary between stones and strictures in ways that matter clinically. In one study comparing patients with biliary strictures to those with bile duct stones, stricture patients had higher bilirubin and alkaline phosphatase (ALP) levels, and their ALP rose disproportionately compared with another liver enzyme called AST. In stone patients, by contrast, acute painful episodes drove sharp spikes in bilirubin and AST rather than ALP, and at the moment of peak enzyme disturbance, AST was elevated more than ALP relative to normal upper limits. The practical takeaway is that a predominant ALP rise points more toward a fixed obstruction such as a stricture or tumor, while acute AST spikes lean toward a stone that is intermittently blocking and unblocking the duct.
Imaging and Diagnosis
Ultrasound is usually the first imaging study ordered because it is fast, widely available, and non-invasive. It can reliably show whether the bile ducts are dilated, which confirms obstruction, but it is much less good at pinpointing the exact cause. In one study of 120 patients, ultrasound correctly identified the cause of the obstruction only about a third of the time, though it could locate the site of obstruction in roughly two-thirds of cases.
Magnetic resonance cholangiopancreatography, or MRCP, is a significant step up. It produces detailed images of the bile and pancreatic ducts without any need for contrast injection into the ducts themselves. In the same study, MRCP identified the cause of obstruction in over 94% of patients and pinpointed the site in over 98%. A separate comparison found MRCP was 100% sensitive for benign diseases and about 96% sensitive for malignancies, outperforming both CT and ultrasound.
Endoscopic ultrasound (EUS) is another powerful tool, particularly for detecting bile duct stones. A meta-analysis comparing EUS directly with MRCP in head-to-head studies found that EUS had a pooled sensitivity of 97% versus 87% for MRCP, with overall diagnostic accuracy significantly favoring EUS. The advantage comes from the ultrasound probe sitting just millimeters from the bile duct inside the duodenum, producing extremely high-resolution images that can pick up small stones MRCP would miss. The trade-off is that EUS is more invasive, requiring sedation and an endoscope passed into the upper digestive tract.
In clinical practice, the choice between MRCP and EUS often depends on the suspected diagnosis and whether an intervention is likely. If stones are the prime suspect and the probability is moderate to high, EUS has the advantage of being immediately followed by therapeutic ERCP during the same sedation session.
Treating Bile Duct Stones
Endoscopic retrograde cholangiopancreatography, known as ERCP, is the standard treatment for bile duct stones. During the procedure an endoscope is passed into the duodenum, the opening of the bile duct is located, and a small cut (sphincterotomy) is made to widen the opening. Stones are then pulled out using balloon catheters or wire baskets. For the majority of patients, this approach clears the duct successfully.
Large stones pose a challenge. Mechanical lithotripsy, which uses a heavy-duty basket to crush the stone, is the traditional fallback, though there is a risk of the basket becoming impacted around the stone, a complication that often requires surgery to resolve. A newer approach combines sphincterotomy with dilation of the duct opening using a large balloon, which allows bigger stones to be extracted without the need for specialized crushing devices.
ERCP is not without risks. Post-procedure pancreatitis is the most common serious complication. In one retrospective study of 500 patients who underwent ERCP for bile duct stones, pancreatitis occurred in about 15% of cases, though the large majority of those episodes were mild. Several factors increased the risk, including a history of prior post-ERCP pancreatitis, difficult cannulation of the duct, and instrumentation of the pancreatic duct.
Stenting for Malignant Obstruction
When a tumor is causing the obstruction and cannot be immediately removed surgically, placing a stent inside the bile duct restores bile flow and relieves jaundice. Stents come in two main types: plastic and self-expanding metal. Metal stents consistently outperform plastic ones. A meta-analysis found that metal stents stayed open significantly longer, required fewer repeat procedures, and were associated with lower rates of cholangitis (roughly 8% versus 21%). Even patient survival was modestly longer with metal stents. A separate meta-analysis confirmed the lower occlusion rates for metal stents in both short-term and long-term follow-up, and across both distal and hilar obstructions.
Metal stents cost more upfront, so plastic stents are sometimes still used in patients with a very short life expectancy or when stenting serves as a temporary bridge before surgery. But for most patients with unresectable malignant obstruction, metal stents are the better choice.
When Endoscopy Fails
If ERCP cannot get past the obstruction, whether because of tumor anatomy, prior surgery that altered the digestive tract, or technical failure, the next option is percutaneous transhepatic biliary drainage (PTBD). A needle is inserted through the skin and liver into a bile duct under imaging guidance, and a drainage catheter is placed. In one study of 68 patients with distal malignant obstruction who had failed ERCP, PTBD had a 100% technical success rate and achieved a meaningful drop in bilirubin in about 85% of cases. After drainage, roughly 30% of patients were able to proceed to surgery, about 40% started chemotherapy, and the remainder received palliative care.
PTBD is more invasive than ERCP and carries its own complications, including bleeding, bile leak, and catheter-related infections. It is generally reserved for situations where the endoscopic route has been tried and failed, or where the anatomy makes ERCP impossible.
Cholangitis and Other Dangerous Complications
Acute cholangitis, an infection of the bile duct, is the most feared complication of biliary obstruction. Stagnant bile becomes a breeding ground for bacteria, and once infection takes hold it can progress rapidly to sepsis. The classic presentation includes jaundice, fever with chills, and right upper abdominal pain. Treatment requires antibiotics plus urgent drainage of the infected bile, typically by ERCP. When that is not possible, percutaneous drainage, endoscopic ultrasound-guided drainage, or even open surgery may be needed.
The gut itself contributes to the danger. When bile stops flowing into the intestine, the normal bacterial population in the gut shifts toward an overgrowth of harmful gram-negative bacteria. Bile normally helps keep these populations in check, and without it, bacteria can cross the intestinal lining into the bloodstream, a process called bacterial translocation. As obstructive jaundice persists, endotoxins from these bacteria become a consistent feature in the blood, compounding the immune suppression that biliary obstruction itself causes. Animal research has shown that restoring bile flow to the intestine helps preserve the integrity of the intestinal lining and reduces bacterial migration.
Systemic Effects Beyond the Liver
Obstructive jaundice is not just a liver problem. Without bile reaching the intestine, fat-soluble vitamins including vitamin K cannot be properly absorbed. Vitamin K is essential for making clotting factors, and its deficiency leads to a bleeding tendency that has been recognized since the late 1930s. Surgeons learned early on that jaundiced patients were prone to unexpected bleeding during operations, and administering vitamin K before surgery became standard practice.
The kidneys are also vulnerable. High levels of circulating bilirubin and bile acids can damage the kidney tubules directly, a condition sometimes called bile cast nephropathy. The combination of altered blood flow in the liver and kidneys, cast formation inside the kidney tubules, and direct cellular injury from bile acids can tip a jaundiced patient into acute kidney failure, particularly after surgery or if dehydration or sepsis is also present.
How Obstructive Jaundice Changes Drug Handling
Because the liver is central to drug metabolism, obstructive jaundice can alter how the body processes medications in clinically important ways. A study of dexmedetomidine, a sedative commonly used in intensive care, found that patients with obstructive jaundice cleared the drug about a third more slowly than patients with healthy livers, and the volume of distribution was reduced by about 29%. Peak blood levels and overall drug exposure were correspondingly higher. For clinicians, that means dose reductions may be needed to avoid excessive sedation.
Not every drug is affected equally, though. A study of etoposide, a chemotherapy agent, found that overall clearance was essentially unchanged in patients with obstructive jaundice. The reason was compensatory: although liver metabolism of etoposide was slightly reduced, the kidneys picked up the slack by excreting more of the drug unchanged. The biliary route of etoposide excretion turned out to be negligible anyway, accounting for less than 2% of an administered dose even in patients with functioning bile ducts. The lesson is that predicting drug behavior in obstructive jaundice requires knowing the drug’s specific elimination pathways rather than assuming the liver is uniformly impaired.
Obstructive Jaundice in Newborns
In infants, the most important cause of obstructive jaundice is biliary atresia, a rare condition in which the bile ducts fail to develop normally or are destroyed early in life. It is the most common surgical cause of cholestatic jaundice in newborns, and without treatment it leads to liver cirrhosis and death within the first few years. The warning signs are persistent jaundice beyond the first two weeks of life, pale stools, and an enlarged liver.
The initial treatment is a surgical procedure called the Kasai portoenterostomy, which bypasses the damaged ducts by connecting the liver directly to a loop of intestine. Timing matters, but the relationship between age at surgery and outcome is not as straightforward as “earlier is always better.” One study found that infants operated on between 51 and 60 days of age actually had the highest two-year survival rates with their native liver, outperforming both those operated on before 40 days and those operated on between 41 and 50 days. This counterintuitive finding may reflect diagnostic and biological factors: very early surgery can sometimes mean a more severe form of the disease or an incomplete diagnostic workup.
Even with a successful Kasai procedure, many children will eventually need a liver transplant. In one cohort followed for five years, about 58% of patients survived with their native liver, while the rest progressed to transplant or died. Jaundice clearance after surgery, typically assessed over the first few months, is a strong predictor of long-term outcome.
Distinguishing Benign from Malignant Strictures
One of the hardest diagnostic puzzles in obstructive jaundice is figuring out whether a bile duct narrowing is caused by cancer or by scar tissue from chronic inflammation. Standard tissue sampling during ERCP misses a significant fraction of malignancies, and the consequences of a false-negative result are serious. An emerging approach involves analyzing cell-free DNA from bile itself. One study tested a next-generation sequencing panel on bile samples and achieved a sensitivity for malignancy of over 96%. Remarkably, among patients whose initial workup classified them as having benign or indeterminate strictures, the bile DNA test identified every case that turned out to be cancer. One of the apparent false positives later developed pancreatic cancer on extended follow-up, suggesting the test may have detected the malignancy before conventional methods could.
This kind of “liquid biopsy” from bile is still largely a research tool, but it highlights where the field is heading. The ability to catch malignant strictures earlier, particularly in patients where standard biopsies are inconclusive, could meaningfully change outcomes for cancers that are currently diagnosed too late for curative surgery.